# US 2023/0404971 A1 · Combination Comprising Abemaciclib and 6-(2,4-Dichlorophenyl)-5-[4-[(3S)-1-(3-Fluoropropyl)Pyrrolidin-3-yl]Oxyphenyl]-8,9-Dihydro-7H-Benzo[7]Annulene-2-Carboxylic Acid

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2023/0404971 A1
- Document ID: US20230404971A1
- Status: Published application
- Kind: A1
- Application number: 18/037,949
- Filed: 2021-11-23
- Published: 2023-12-21
- Earliest claimed: 2020-11-23
- Assignees: Sanofi
- Applicants: Sanofi
- Inventors: Monsif Bouaboula; Zhuyan Guo; Fangxian Sun
- Web page: https://patentgrep.com/patent/US20230404971A1

## CPC

- A61K 31/40: having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K 31/4015: having oxo groups directly attached to the heterocyclic ring, e.g. piracetam, ethosuximide
- A61K 31/506: not condensed and containing further heterocyclic rings
- A61P 35/00: Antineoplastic agents
- A61P 35/04: specific for metastasis
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

Herein are provided a combination of abemaciclib and of 6-(2,4-dichlorophenyl)-5-[4-[(3S)-1-(3-fluoropropyl)pyrrolidin-3-yl]oxyphenyl]-8,9-dihydro-7H-benzo[7]annulene-2-carboxylic acid, or a pharmaceutically acceptable salt thereof, a pharmaceutical composition containing such a combination, and the therapeutic uses thereof, in particular for the treatment of cancer, including breast cancer.

## Claims

### Claim 1

A combination comprising 6-(2,4-dichlorophenyl)-5-[4-[(3S)-1-(3-fluoropropyl)pyrrolidin-3-yl]oxyphenyl]-8,9-dihydro-7H-benzo[7]annulene-2-carboxylic acid, or a pharmaceutically acceptable salt thereof, and abemaciclib.

### Claim 2 (depends on 1)

The combination according to claim 1, showing therapeutic synergy.

### Claim 3 (depends on 1, 2)

The combination according to claim 1 or claim 2, for use in the treatment of cancer.

### Claim 4 (depends on 3)

The combination for use according to claim 3, wherein the cancer is breast cancer.

### Claim 5 (depends on 1, 2, 3, 4)

The combination according to any of claims 1 to 4, wherein 6-(2,4-dichlorophenyl)-5-[4-[(3S)-1-(3-fluoropropyl)pyrrolidin-3-yl]oxyphenyl]-8,9-dihydro-7H-benzo[7]annulene-2-carboxylic acid, or a pharmaceutically acceptable salt thereof, and abemaciclib are administered simultaneously or spaced out over a period of time.

### Claim 6

A pharmaceutical composition comprising 6-(2,4-dichlorophenyl)-5-[4-[(3S)-1-(3-fluoropropyl)pyrrolidin-3-yl]oxyphenyl]-8,9-dihydro-7H-benzo[7]annulene-2-carboxylic acid, or a pharmaceutically acceptable salt thereof, and abemaciclib, and at least one pharmaceutically acceptable excipient.

### Claim 7 (depends on 6)

The pharmaceutical composition according to claim 6, for use in the treatment of cancer.

### Claim 8 (depends on 7)

The pharmaceutical composition for use according to claim 7, wherein the cancer is breast cancer.

### Claim 9

Compound 6-(2,4-dichlorophenyl)-5-[4-[(3S)-1-(3-fluoropropyl)pyrrolidin-3-yl]oxyphenyl]-8,9-dihydro-7H-benzo[7]annulene-2-carboxylic acid, or a pharmaceutically acceptable salt thereof for use in the treatment of cancer by co-administration with abemaciclib.

### Claim 10 (depends on 8)

The compound for use in the treatment of cancer according to claim 8, which is administered separately, simultaneously, or spaced out over time, with abemaciclib.

### Claim 11

Abemaciclib for use in the treatment of cancer by co-administration with compound 6-(2,4-dichlorophenyl)-5-[4-[(3S)-1-(3-fluoropropyl)pyrrolidin-3-yl]oxyphenyl]-8,9-dihydro-7H-benzo[7]annulene-2-carboxylic acid, or a pharmaceutically acceptable salt thereof.

### Claim 12 (depends on 11)

Abernaciclib for use in the treatment of cancer according to claim 11, which is administered separately, simultaneously or spaced out over time, with compound 6(2,4-dichlorophenyl)-5-[4-[(3S)-1-(3-fluoropropyl)pyrrolidin-3-yl]oxyphenyl]-8,9-dihydro-7H-benzo[7]annulene-2- carboxylic acid, or a pharmaceutically acceptable salt thereof.

### Claim 13

A method of treating cancer comprising administering to a patient in need thereof a therapeutically effective amount of compound 6-(2,4-dichlorophenyl)-5-[4-[(3S)-1-(3-fluoropropyl)pyrrolidin-3-yl]oxyphenyl]-8,9-dihydro-7H-benzo[7]annulene-2-carboxylic acid, or a pharmaceutically acceptable salt thereof, in combination with a therapeutically effective amount of abemaciclib.

### Claim 14

A method of treating cancer in a patient who is on therapy with compound 6-(2,4-dichlorophenyl)-5-[4-[(3S)-1-(3-fluoropropyl)pyrrolidin-3-yl]oxyphenyl]-8,9-dihydro-7H-benzo[7]annulene-2-carboxylic acid, or a pharmaceutically acceptable salt thereof, comprising administering to said patient an effective amount of abemaciclib.

### Claim 15

A method of treating cancer in a patient on stable treatment with compound 6-(2,4-dichlorophenyl)-5-[4-[(3S)-1-(3-fluoropropyl)pyrrolidin-3-yl]oxyphenyl]-8,9-dihydro-7H-benzo[7]annulene-2-carboxylic acid, or a pharmaceutically acceptable salt thereof, comprising administering to said patient a therapeutically effective amount of abemaciclib.

### Claim 16

A method of treating cancer comprising administering to a patient in need thereof a therapeutically effective amount of abemaciclib, wherein said patient is also on therapy with compound 6-(2,4-dichlorophenyl)-5-[4-[(3S)-1-(3-fluoropropyl)pyrrolidin-3-yl]oxyphenyl]-8,9-dihydro-7H-benzo[7]annulene-2-carboxylic acid, or a pharmaceutically acceptable salt thereof.

### Claim 17

A pharmaceutical kit comprising:
(i) a first pharmaceutical composition comprising 6-(2,4-dichlorophenyl)-5-[4-[(3S)-1-(3-fluoropropyl)pyrrolidin-3-yl]oxyphenyl]-8,9-dihydro-7H-benzo[7]annulene-2-carboxylic acid, or a pharmaceutically acceptable salt thereof, and at least one pharmaceutically acceptable excipient;
(ii) a second pharmaceutical composition comprising abemaciclib, and at least one pharmaceutically acceptable excipient;
wherein the first pharmaceutical composition and the second pharmaceutical composition are in separate compartments and are intended to be independently administered, each administration with regards to the other one being simultaneous or spaced out over time.
